Actively Recruiting

Phase 3
Age: 16Years - 80Years
All Genders
NCT07184944

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Led by Sanofi · Updated on 2026-05-14

751

Participants Needed

15

Research Sites

425 weeks

Total Duration

On this page

Sponsors

S

Sanofi

Lead Sponsor

T

Teva Branded Pharmaceutical Products R&D LLC

Collaborating Sponsor

AI-Summary

What this Trial Is About

This is a multicenter, randomized, double-blind, placebo-controlled, maintenance, Phase 3 study to evaluate the efficacy and safety of duvakitug in participants with moderately to severely active Crohn's Disease (CD). Study details include: The study duration may be up to 286 weeks including: * 40-week Pivotal Maintenance Sub-Study * 240-week Open-Label Extension (OLE) Sub-Study * 45-day Follow-Up visit Note: For the participants who do not enroll into OLE Sub-Study, the duration will be up to 46 weeks, including the 40-week maintenance period and a 45-day follow-up visit. The treatment duration may be up to 280 weeks including: * 40 weeks in the Pivotal Maintenance Sub-Study * 240 weeks in OLE Sub-Study The total number of on-site visits will be up to 43: - 21 visits in the Pivotal Maintenance Sub-Study - 22 visits in the OLE Sub-Study

CONDITIONS

Official Title

A Maintenance Study to Investigate the Efficacy and Safety of Duvakitug in Participants With Moderately to Severely Active Crohn's Disease

Who Can Participate

Age: 16Years - 80Years
All Genders

Eligibility Criteria

Eligible

You may qualify if you...

  • Participants aged 18 to 80 years at baseline (participants 16 to under 18 years allowed if Tanner stage 5)
  • Participants who achieved clinical response and completed endoscopy in the STARSCAPE-1 study for the Pivotal Maintenance Sub-Study
  • Participants who complete the Pivotal Maintenance Sub-Study or the TV48574-IMM-20038 study for the Open-Label Extension Sub-Study
Not Eligible

You will not qualify if you...

  • Participants with medical or compliance conditions deemed unsuitable by the investigator
  • Participants with known hypersensitivity to duvakitug making them unsuitable for the study

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Trial Site Locations

Total: 15 locations

1

Peak Gastroenterology Associates - Colorado Springs-Site Number: 8400039

Colorado Springs, Colorado, United States, 80907

Actively Recruiting

2

Clinical Research of Osceola-Site Number: 8400013

Kissimmee, Florida, United States, 34741

Actively Recruiting

3

Bioresearch Partner-Kendale Lakes-Site Number: 8400053

Miami, Florida, United States, 33175

Actively Recruiting

4

NMC Research LLC-Site Number: 8400033

Tampa, Florida, United States, 33607

Actively Recruiting

5

GI Alliance - Baton Rouge-Site Number: 8400129

Baton Rouge, Louisiana, United States, 70809

Actively Recruiting

6

Gateway Gastroenterology-Site Number: 8400097

St Louis, Missouri, United States, 63141

Actively Recruiting

7

NYU Langone Health-Site Number: 8400091

New York, New York, United States, 10016

Actively Recruiting

8

New York Gastroenterology Associates-Site Number: 8400009

New York, New York, United States, 10075

Actively Recruiting

9

Cross Creek Medical Clinic-Site Number: 8400057

Fayetteville, North Carolina, United States, 28304

Actively Recruiting

10

Ohio Gastroenterology Group Inc.-Site Number: 8400006

Columbus, Ohio, United States, 43202

Actively Recruiting

11

OSU Wexner Medical Center-Site Number: 8400077

Columbus, Ohio, United States, 43210

Actively Recruiting

12

Gastroenterology Research of San Antonio LLC-Site Number: 8400054

San Antonio, Texas, United States, 78229

Actively Recruiting

13

Tyler Research Institute LLC-Site Number: 8400095

Tyler, Texas, United States, 75701

Actively Recruiting

14

Gastroenterology Associates of Western Michigan-Site Number: 8400060

Wyoming, Wyoming, United States, 49519

Actively Recruiting

15

Investigational Site Number : 1240003

Toronto, Canada, M6A 3B4

Actively Recruiting

Loading map...

Research Team

T

Trial Transparency email recommended (Toll free for US & Canada)

CONTACT

How is the study designed?

Study Type

INTERVENTIONAL

Masking

QUADRUPLE

Allocation

RANDOMIZED

Model

PARALLEL

Primary Purpose

TREATMENT

Number of Arms

4

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here